摘要
目的探讨胃癌前病变与胃窦部P物质(SP)、血管活性肠肽(VIP)、降钙素基因相关肽(CGRP)的关系及中药制剂阻癌胃泰的治疗机制。方法采用N-甲基-N-硝基-N-亚硝基胍(MNNG)合并胃黏膜机械损伤方法制作了胃癌前病变大鼠模型。选用中药制剂阻癌胃泰进行预防和治疗给药,观察了大鼠模型胃黏膜病理形态变化,同时用免疫组化法检测了SP、VIP、CGRP含量变化。结果胃窦部SP、CGRP的含量中药组比西药组有明显提高(P＜0．05),但VIP含量比较差异无显著性。(P＞0．05)。结论无论是预防给药还是治疗给药,阻癌胃泰能提高大鼠胃窦部SP、VIP、CGRP的含量。
Objective To explore the relationship between precancerous lesions of gastric antrum and sub- stance P(SP),vasoactive intestinal peptide(VIP),calcitonin gene-related peptide(CGRP),and the therapeutic mechanism of Zu ai Weitai Granule(ZWG),a TCM preparation.Methods The rat model of precancerous lesions of gastric carcinoma was induced by the combined method of N-methyl N -nitrosoguani-dine(MNNG)and mechani- cal injury on gastric mucosa.The pathologic morphological changes of gastric mucosa were observed afte...
出处
《中国中西医结合杂志》
CAS
CSCD
北大核心
2006年第S1期92-94,共3页
Chinese Journal of Integrated Traditional and Western Medicine
基金
辽宁省科委资助项目(No:2001101028)
关键词
胃癌前病变
阻癌胃泰
P物质
血管活性肠肽
降钙素基因相关肽
precancerous lesions of gastric carcinoma
Zu ai Weitai Granule
substance P
vasoactive intestinal peptide
calcitonin gene-related peptide
